Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIUM GLUCEPTATE vs MICRO-K 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcium gluceptate is a calcium salt that dissociates to provide calcium ions, which are essential for various physiological processes including nerve conduction, muscle contraction, blood coagulation, and cardiac function. It acts as a calcium replenisher.
Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride is absorbed from the gastrointestinal tract and distributes throughout the body. The microencapsulated formulation allows for gradual release of potassium, minimizing gastrointestinal irritation.
Treatment of hypocalcemia,Calcium supplementation in patients requiring parenteral calcium,Treatment of hypermagnesemia,Cardiac resuscitation (as an adjunct),Treatment of calcium channel blocker overdose
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving digitals or diuretics for congestive heart failure, hepatic cirrhosis, or nephrotic syndrome,Correction of hypokalemia in patients with hypertension on long-term diuretic therapy
IV: 2-4 mg/kg elemental calcium (5-10 m L of 0.45 m Eq/m L solution) administered slowly over 10-20 minutes. May repeat if needed. Maximum dose: 20 m L per infusion.
10 m Eq (2 capsules) orally once daily, or 20 m Eq (2 capsules) twice daily, or as directed by physician. Maximum 100 m Eq/day.
Terminal elimination half-life: 2-4 hours (normal renal function); prolonged to 12-24 hours in renal impairment.
Not applicable; potassium is not cleared by first-order kinetics. Whole-body potassium turnover half-life is approximately 30 days, but this is not clinically relevant for supplementation.
Calcium gluceptate is not metabolized; it dissociates into calcium ions and gluceptate. Calcium ions are excreted primarily in feces and urine, with renal handling involving reabsorption and secretion.
Potassium is not metabolized. Approximately 90% of ingested potassium is excreted in the urine, with the remainder excreted in feces and sweat. There is no hepatic metabolism.
Renal: >90% excreted unchanged in urine. Biliary/fecal: <5%.
Primarily renal: 90% of absorbed potassium is excreted in urine as potassium ions; 10% eliminated in feces via biliary and intestinal secretion.
~45% bound to albumin.
0% bound to serum proteins; free ion in serum.
0.15-0.25 L/kg; represents distribution mainly in extracellular fluid.
Total body water: 0.5 L/kg; distributes primarily intracellularly (98% of body potassium is intracellular), but Vd is not a clinically relevant parameter for potassium.
IV: 100%; IM: not well characterized; oral: negligible (absorbed poorly, systemic bioavailability <1% as calcium gluceptate dissociates in GI tract).
Oral (microencapsulated): 90-100% relative to intravenous; absorption is nearly complete via the gastrointestinal tract.
GFR >50: No adjustment. GFR 30-50: Reduce dose by 25%. GFR <30: Reduce dose by 50% and monitor serum calcium closely. Dialysis: Dose after hemodialysis.
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: reduce dose by 50% or use with caution. GFR <10 m L/min: contraindicated or use with extreme caution.
No dose adjustment required for hepatic impairment. However, monitor ionized calcium in severe hepatic failure due to altered binding proteins.
No specific Child-Pugh based modifications; use with caution in severe hepatic impairment due to risk of hyperkalemia.
Neonates and infants: 100-200 mg elemental calcium/kg/day IV divided every 6 hours. Children: 200-500 mg elemental calcium/kg/day IV divided every 6 hours. Maximum: 1 g elemental calcium per dose.
Children: 1-2 m Eq/kg/day in divided doses, not to exceed 20 m Eq per dose or 100 m Eq/day. Minimum dosing weight not specified; safety and efficacy not established in premature infants.
Use lower initial doses (e.g., 1-2 mg/kg elemental calcium) due to reduced renal function and increased risk of hypercalcemia. Monitor serum calcium and phosphate levels.
Elderly: start with lower doses (e.g., 10 m Eq once daily) due to age-related renal function decline; monitor serum potassium and renal function frequently.
No FDA black box warning.
None
Risk of hypercalcemia, especially in patients with renal impairment,Avoid rapid intravenous administration to prevent cardiac arrest,Use with caution in patients with sarcoidosis or digitalis toxicity,Monitor serum calcium levels during therapy,Extravasation may cause tissue necrosis
Hyperkalemia risk; use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia,Gastrointestinal irritation and ulceration; do not crush or chew tablets,May increase serum potassium levels in patients with adrenal insufficiency or diabetes,Use caution with potassium-sparing diuretics or ACE inhibitors
Hypercalcemia,Hypersensitivity to calcium gluceptate or any component,Ventricular fibrillation,Patients with known calcium-containing calculi
Severe renal impairment with oliguria or azotemia,Addison's disease,Acute dehydration,Heat cramps,Hyperkalemia from any cause,Concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride)
Avoid high-calcium foods (dairy, fortified cereals) during acute therapy to prevent hypercalcemia. Limit vitamin D-rich foods (fatty fish, fortified milk). Do not take oral calcium within 1 hour of iron or thyroid medications. Avoid excessive caffeine and alcohol.
Avoid high-potassium foods (e.g., bananas, oranges, tomatoes, potatoes, salt substitutes) unless directed otherwise; intake may need to be restricted or monitored.
Calcium gluceptate is a calcium salt used for calcium supplementation. No specific teratogenic effects are reported; calcium is essential for fetal development. First trimester: No increased risk of major malformations. Second and third trimesters: Adequate intake supports fetal skeletal mineralization; excess may cause hypercalcemia in the infant. No known teratogenicity.
Potassium chloride is not associated with fetal malformations. In all trimesters, excessive potassium intake can cause maternal hyperkalemia, which may lead to fetal arrhythmias or adverse outcomes. Recommended intakes are safe.
Calcium gluceptate is considered safe during breastfeeding. Calcium is naturally present in breast milk; supplementation does not significantly alter milk calcium levels. M/P ratio not established, but endogenous calcium transport suggests minimal risk. Use with caution in mothers with hypercalcemia.
Potassium is a normal constituent of breast milk with an M/P ratio of approximately 0.1-0.2. Supplemental potassium is not expected to cause adverse effects in nursing infants at usual maternal doses.
No specific dose adjustment required in pregnancy; maintain recommended daily intake (1000-1300 mg elemental calcium). Pharmacokinetic changes in pregnancy (increased absorption, renal clearance) may slightly alter requirements, but standard doses are safe. Intravenous use should be adjusted based on serum calcium monitoring.
No specific dose adjustment required for pregnancy. However, increased plasma volume and renal blood flow during pregnancy may lower serum potassium, potentially requiring higher doses for hypokalemia treatment. Individualize based on serum potassium monitoring.
Calcium gluceptate is used for acute hypocalcemia, hyperkalemia cardiotoxicity, and hypermagnesemia. Administer IV slowly (0.5-1 m L/min) to avoid arrhythmias; monitor ECG during infusion. Do not mix with bicarbonate, phosphate, or sulfate-containing solutions. Extravasation causes tissue necrosis; use central line for peripheral therapy. Correct hypomagnesemia before calcium therapy to prevent refractory hypocalcemia.
Micro-K 10 (potassium chloride extended-release) is used for hypokalemia. Avoid in severe renal impairment (Cr Cl <30 m L/min) due to risk of hyperkalemia. Do not crush or chew capsules; administer with food to reduce GI irritation. Monitoring serum potassium levels is essential, especially in patients on digoxin or diuretics. Use with caution in patients with significant heart block or metabolic acidosis.
Report any burning or pain at injection site immediately.,Avoid taking calcium supplements or antacids without consulting your doctor.,Tell your doctor if you have kidney stones, parathyroid disorders, or heart disease.,Do not stop other calcium medications abruptly.,Seek emergency care for difficulty breathing or chest tightness after infusion.
Take this medication exactly as prescribed, usually once daily with food.,Do not crush, chew, or open the capsule; swallow whole.,Do not use salt substitutes or potassium supplements unless instructed by your doctor.,Seek medical attention if you experience muscle weakness, irregular heartbeat, or signs of GI obstruction (severe stomach pain, vomiting, or black stools).,Tell your doctor about all medications, especially diuretics or ACE inhibitors.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIUM GLUCEPTATE vs MICRO-K 10, answered by our medical review team.
CALCIUM GLUCEPTATE is a Electrolyte Supplement that works by Calcium gluceptate is a calcium salt that dissociates to provide calcium ions, which are essential for various physiological processes including nerve conduction, muscle contraction, blood coagulation, and cardiac function. It acts as a calcium replenisher.. MICRO-K 10 is a Electrolyte Supplement (Potassium) that works by Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride is absorbed from the gastrointestinal tract and distributes throughout the body. The microencapsulated formulation allows for gradual release of potassium, minimizing gastrointestinal irritation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIUM GLUCEPTATE and MICRO-K 10 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIUM GLUCEPTATE is: IV: 2-4 mg/kg elemental calcium (5-10 m L of 0.45 m Eq/m L solution) administered slowly over 10-20 minutes. May repeat if needed. Maximum dose: 20 m L per infusion.. The standard adult dose of MICRO-K 10 is: 10 m Eq (2 capsules) orally once daily, or 20 m Eq (2 capsules) twice daily, or as directed by physician. Maximum 100 m Eq/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIUM GLUCEPTATE and MICRO-K 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIUM GLUCEPTATE is classified as Category C. Calcium gluceptate is a calcium salt used for calcium supplementation. No specific teratogenic effects are reported; calcium is essential for fetal development. First trimester: No. MICRO-K 10 is classified as Category C. Potassium chloride is not associated with fetal malformations. In all trimesters, excessive potassium intake can cause maternal hyperkalemia, which may lead to fetal arrhythmias or. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.